enasidenib
Showing 1 - 17 of 17
Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer Trial in Edmonton, Toronto (Enasidenib, Venetoclax)
Active, not recruiting
- Acute Myeloid Leukemia
- +3 more
- Enasidenib
- Venetoclax
-
Edmonton, Alberta, Canada
- +1 more
Jan 31, 2023
Acute Myeloid Leukemia (AML) Trial in United States (Gilteritinib, Ivosidenib, Enasidenib)
Not yet recruiting
- Acute Myeloid Leukemia (AML)
- Gilteritinib
- +2 more
-
Basking Ridge, New Jersey
- +6 more
Mar 3, 2023
Hepatic Impairment Trial in Miami, Orlando, Knoxville (Enasidenib)
Recruiting
- Hepatic Impairment
- Enasidenib
-
Miami, Florida
- +4 more
Nov 27, 2022
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Baltimore, Boston, Columbus (Enasidenib)
Active, not recruiting
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Enasidenib
-
Baltimore, Maryland
- +3 more
Aug 8, 2022
Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance Trial in United States
Recruiting
- Clonal Cytopenia of Undetermined Significance
- CCUS Clonal Cytopenia of Undetermined Significance
- Enasidenib
-
Rochester, Minnesota
- +11 more
Jan 24, 2023
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Decitabine and
Recruiting
- Acute Myeloid Leukemia
- +2 more
- Decitabine and Cedazuridine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jun 29, 2022
Acute Myeloid Leukemia Trial in Houston (Decitabine and Cedazuridine, Enasidenib, Gilteritinib)
Recruiting
- Acute Myeloid Leukemia
- Decitabine and Cedazuridine
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Aug 10, 2022
Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia Trial in Baltimore,
Active, not recruiting
- Acute Myeloid Leukemia
- +6 more
- Azacitidine
- +2 more
-
Baltimore, Maryland
- +2 more
Feb 25, 2022
Accelerated/Blast-phase Myeloproliferative Tumor, Chronic-phase Myelofibrosis, IDH2 Mutation Trial in Canada, United States
Recruiting
- Accelerated/Blast-phase Myeloproliferative Neoplasm
- +2 more
- Ruxolitinib
- Enasidenib
-
Scottsdale, Arizona
- +10 more
May 9, 2022
Acute Myeloid Leukemia Trial in Columbus (Azacitidine, Biopsy, Enasidenib)
Not yet recruiting
- Acute Myeloid Leukemia
- Azacitidine
- +4 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Jun 30, 2022
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Canada, United States (Enasidenib, Enasidenib
Recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Enasidenib
- Enasidenib Mesylate
-
Birmingham, Alabama
- +17 more
Jun 21, 2021
IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation Trial in Chicago (Ivosidenib, Enasidenib, Fedratinib)
Recruiting
- IDH Mutation
- +4 more
- Ivosidenib
- +2 more
-
Chicago, IllinoisUniversity of Chicago Medical Center
Nov 12, 2021
Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to
Withdrawn
- Blasts Under 5 Percent of Peripheral Blood White Cells
- +4 more
- Enasidenib
- Hematopoietic Cell Transplantation
-
Buffalo, New York
- +1 more
Mar 8, 2021
Acute Myeloid Leukemia Trial in United States (CPX-351, Venetoclax, Midostaurin)
Active, not recruiting
- Acute Myeloid Leukemia
- CPX-351
- +3 more
-
Duarte, California
- +9 more
Jan 3, 2023
Hepatic Impairment Trial in United States (Enasidenib)
Completed
- Hepatic Impairment
- Enasidenib
-
Lakewood, Colorado
- +4 more
Jul 16, 2020
Healthy Volunteers Trial in Austin (Enasidenib)
Completed
- Healthy Volunteers
- Enasidenib
-
Austin, TexasPPD Development, LP
Mar 13, 2020
Children, Adolescents and Young Adults With Refractory or Recurrent Malignancies Trial in Worldwide (Ribociclib, Topotecan,
Unknown status
- Children, Adolescents and Young Adults With Refractory or Recurrent Malignancies
- Ribociclib
- +9 more
-
Copenhagen, Denmark
- +6 more
Feb 23, 2021